Cancelliero K M, Durigan J L Q, Vieira R P, Silva C A, Polacow M L O
Departamento de Fisioterapia, Universidade Federal de São Carlos, São Carlos, SP, Brasil.
Braz J Med Biol Res. 2008 Dec;41(12):1054-8. doi: 10.1590/s0100-879x2008001200003.
The aim of the present study was to evaluate the effect of joint immobilization on morphometric parameters and glycogen content of soleus muscle treated with clenbuterol. Male Wistar (3-4 months old) rats were divided into 4 groups (N = 6 for each group): control, clenbuterol, immobilized, and immobilized treated with clenbuterol. Immobilization was performed with acrylic resin orthoses and 10 microg/kg body weight clenbuterol was administered subcutaneously for 7 days. The following parameters were measured the next day on soleus muscle: weight, glycogen content, cross-sectional area, and connective tissue content. The clenbuterol group showed an increase in glycogen (81.6%, 0.38 +/- 0.09 vs 0.69 +/- 0.06 mg/100 g; P < 0.05) without alteration in weight, cross-sectional area or connective tissue compared with the control group. The immobilized group showed a reduction in muscle weight (34.2%, 123.5 +/- 5.3 vs 81.3 +/- 4.6 mg; P < 0.05), glycogen content (31.6%, 0.38 +/- 0.09 vs 0.26 +/- 0.05 mg/100 mg; P < 0.05) and cross-sectional area (44.1%, 2574.9 +/- 560.2 vs 1438.1 +/- 352.2 microm(2); P < 0.05) and an increase in connective tissue (216.5%, 8.82 +/- 3.55 vs 27.92 +/- 5.36%; P < 0.05). However, the immobilized + clenbuterol group showed an increase in weight (15.9%; 81.3 +/- 4.6 vs 94.2 +/- 4.3 mg; P < 0.05), glycogen content (92.3%, 0.26 +/- 0.05 vs 0.50 +/- 0.17 mg/100 mg; P < 0.05), and cross-sectional area (19.9%, 1438.1 +/- 352.2 vs 1724.8 +/- 365.5 microm(2); P < 0.05) and a reduction in connective tissue (52.2%, 27.92 +/- 5.36 vs 13.34 +/- 6.86%; P < 0.05). Statistical analysis was performed using Kolmogorov-Smirnov and homoscedasticity tests. For the muscle weight and muscle glycogen content, two-way ANOVA and the Tukey test were used. For the cross-sectional area and connective tissue content, Kruskal-Wallis and Tukey tests were used. This study emphasizes the importance of anabolic pharmacological protection during immobilization to minimize skeletal muscle alterations resulting from disuse.
本研究的目的是评估关节固定对用克伦特罗治疗的比目鱼肌形态计量学参数和糖原含量的影响。雄性Wistar大鼠（3 - 4月龄）被分为4组（每组N = 6）：对照组、克伦特罗组、固定组和固定并用克伦特罗治疗组。用丙烯酸树脂矫形器进行固定，皮下注射10μg/kg体重的克伦特罗持续7天。次日在比目鱼肌上测量以下参数：重量、糖原含量、横截面积和结缔组织含量。与对照组相比，克伦特罗组糖原增加（81.6%，0.38±0.09对0.69±0.06mg/100g；P < 0.05），而重量、横截面积或结缔组织无变化。固定组肌肉重量减少（34.2%，123.5±5.3对81.3±4.6mg；P < 0.05）、糖原含量减少（31.6%，0.38±0.09对0.26±0.05mg/100mg；P < 0.05）和横截面积减少（44.1%，2574.9±560.2对1438.1±352.2μm²；P < 0.05），结缔组织增加（216.5%，8.82±3.55对27.92±5.36%；P < 0.05）。然而，固定 + 克伦特罗组重量增加（15.9%；81.3±4.6对94.2±4.3mg；P < 0.05）、糖原含量增加（92.3%，0.26±0.05对0.50±0.17mg/100mg；P < 0.05）和横截面积增加（19.9%，1438.1±352.2对1724.8±365.5μm²；P < 0.05），结缔组织减少（52.2%，27.92±5.36对13.34±6.86%；P < 0.05）。使用Kolmogorov - Smirnov和同质性检验进行统计分析。对于肌肉重量和肌肉糖原含量，使用双向方差分析和Tukey检验。对于横截面积和结缔组织含量，使用Kruskal - Wallis和Tukey检验。本研究强调了在固定期间进行合成代谢药物保护以最小化因废用导致的骨骼肌改变的重要性。
